Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Long-Term Follow-up of Measles Antibodies
This study has been completed.
Sponsors and Collaborators: Bandim Health Project
Danish Council for Development Research
Novo Nordisk
Fonden til Lægevidenskabens Fremme. E-mail: cphapmfond@maersk.com.
Medical Research Council Laboratories, Gambia
Information provided by: Bandim Health Project
ClinicalTrials.gov Identifier: NCT00168571
  Purpose

Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would be the first to describe the persistence of measles antibodies after two doses of measles vaccine, and the study would allow us to identify unprotected children and offer them revaccination. Since persistence of measles antibodies is of crucial importance to measles control, the study will contribute significantly to the existing knowledge and might have important implications for future eradication programmes.


Condition Intervention Phase
Measles
Biological: Measles vaccine
Phase IV

MedlinePlus related topics: Measles
Drug Information available for: Immunoglobulins Globulin, Immune Measles Vaccine
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Long-Term Follow-up of Protective Measles Antibodies in the Two-Dose Study of Standard-Titre Measles Vaccine in Guinea-Bissau

Further study details as provided by Bandim Health Project:

Primary Outcome Measures:
  • Measles antibody level

Estimated Enrollment: 1960
Study Start Date: March 2002
Study Completion Date: January 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   6 Years to 10 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Children participating in the Two-dose trial (Non-Specific Effects of Standard Titre Measles Vaccination, Protocol ID: IC18-CT95-0011-Twodose1)

Exclusion Criteria: Severe illness requiring hospitalisation

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168571

Locations
Guinea-Bissau, Apartado 861
Bandim Health Project
Bissau, Apartado 861, Guinea-Bissau, 1004 Bissau Codex
Sponsors and Collaborators
Bandim Health Project
Danish Council for Development Research
Novo Nordisk
Fonden til Lægevidenskabens Fremme. E-mail: cphapmfond@maersk.com.
Medical Research Council Laboratories, Gambia
Investigators
Study Director: PETER AABY, MSc, Dr Med Bandim Health Project
Principal Investigator: MAY-LILL GARLY, PHD, DTM&H Bandim Health Project
  More Information

Statens Serum Institut, Denmark  This link exits the ClinicalTrials.gov site

Study ID Numbers: LTAB-2288/2292-Twodose1, NOVO-2288, Lægevidenskabens Fremme-2292
Study First Received: September 9, 2005
Last Updated: April 13, 2007
ClinicalTrials.gov Identifier: NCT00168571  
Health Authority: Guinea-Bissau: Ministry of Health;   Gambia: MRC Ethics Committee

Keywords provided by Bandim Health Project:
Measles vaccine
Measles
Measles antibodies
Immunisation
Low income country
Guinea-Bissau
Bandim Health Project
Measles antibody level

Study placed in the following topic categories:
Virus Diseases
Antibodies
Paramyxoviridae Infections
Measles
Immunoglobulins

Additional relevant MeSH terms:
RNA Virus Infections
Morbillivirus Infections
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Mononegavirales Infections

ClinicalTrials.gov processed this record on January 13, 2009